Liquid biopsy tracking for immunotherapy-treated melanoma
Part of Cancer, Skin clinical trials.
This study looks at whether a simple blood test can track how well immunotherapy is working in people with advanced melanoma. It might help doctors see if the treatment is effective earlier than with scans alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with melanoma.
- Your melanoma is advanced (stage III or IV) and cannot be removed with surgery.
- Your disease has shown growth on scans within the last month.
- You have had at least one round of immunotherapy for melanoma.
- You are currently on active treatment or having regular scans to check for recurrence.
- You are over 16 years old and have not had HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This study looks at using a blood test that detects tiny pieces of cancer DNA (called ctDNA) to help decide how long patients with advanced melanoma should stay on immunotherapy. It may help some patients safely stop treatment earlier if the blood test shows the cancer is under control.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.